Name: ARROWHEAD PHARMACEUTICALS IN (ARWR) Stock
Brand: ARROWHEAD PHARMACEUTICALS IN
Rating: 7.5 (3 reviews)

ARWR Latest News, Press Relases and Analysis

All

Press Releases

11 days ago - By: Chartmill

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) Reports Strong Q4 2025 Revenue Beat and First FDA Approval

4 days ago - By: Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia

5 days ago - By: Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals to Participate in Upcoming December 2025 Conferences

9 days ago - By: The Motley Fool

Why Arrowhead Pharmaceuticals Stock Surged by Over 23% Today

10 days ago - By: Stocktwits - Mentions: IWMW EAOR MS

Arrowhead Pharmaceuticals Stock Jumps 22% After Morgan Stanley Hikes Price Target

11 days ago - By: The Motley Fool

Arrowhead (ARWR) Q4 2025 Earnings Call Transcript

11 days ago - By: Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results

12 days ago - By: Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics

17 days ago - By: Benzinga - Mentions: HSIC HUM LLY NVO ...

10 Health Care Stocks With Whale Alerts In Today's Session

18 days ago - By: Benzinga

FDA Clears Arrowhead Pharma's First-Ever Home Injection For Rare Fat Disorder

18 days ago - By: Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

a month ago - By: Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Year-End Results

a month ago - By: Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals to Participate in Upcoming November 2025 Conferences

a month ago - By: Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

2 months ago - By: Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Novartis

2 months ago - By: Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals Files CTA for Investigational ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

3 months ago - By: Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals Files Complaint for Declaratory Judgment Against Ionis Pharmaceuticals

3 months ago - By: Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies

3 months ago - By: Stocktwits - Mentions: NVS

Arrowhead Stock Rockets 11% Today – Retail Says $200M Upfront Payment From Novartis Collaboration Is ‘Hell Of A Deal’

3 months ago - By: Investor's Business Daily - Mentions: NVS

Arrowhead Pharma Jumps After Inking A Deal Worth Up To $2.2 Billion

3 months ago - By: Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement

3 months ago - By: Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals to Participate in Upcoming September 2025 Conferences

4 months ago - By: Yahoo Finance - Mentions: HI

Goodbye, Mag 7! These 3 Buy-Rated Small-Cap Stocks Are Starting to Outperform.

4 months ago - By: Yahoo Finance - Mentions: SRPT

Arrowhead (ARWR) Climbs 24.9% on $100-Million Licensing Revenue

4 months ago - By: Stocktwits - Mentions: SRPT

This Analyst Says Sarepta Lost Credibility By Exiting Arrowhead At A Loss, But Retail Sees Stock Hitting $30 By Next Week

4 months ago - By: Investor's Business Daily - Mentions: SRPT

Sarepta Sells Arrowhead Stake To Stretch Its Cash Runway; And One Stock Dives

4 months ago - By: Stocktwits - Mentions: SRPT

Sarepta Keeps Retail Traders Bullish As Stock Surges On $100M Milestone Payment To Arrowhead In Genetic Disorder Trial

4 months ago - By: Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals Redeems Approximately $50 Million of Arrowhead Stock and Will Receive Approximately $50 Million in Cash in Satisfaction of Milestone from Sarepta Therapeutics

4 months ago - By: Arrowhead Pharmaceuticals, Inc.

ARROWHEAD PHARMACEUTICALS IN (ARWR) Stock News

ARWR Latest News, Press Relases and Analysis

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) Reports Strong Q4 2025 Revenue Beat and First FDA Approval

Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia

Arrowhead Pharmaceuticals to Participate in Upcoming December 2025 Conferences

Why Arrowhead Pharmaceuticals Stock Surged by Over 23% Today

Arrowhead Pharmaceuticals Stock Jumps 22% After Morgan Stanley Hikes Price Target

Arrowhead (ARWR) Q4 2025 Earnings Call Transcript

Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results

Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics

10 Health Care Stocks With Whale Alerts In Today's Session

FDA Clears Arrowhead Pharma's First-Ever Home Injection For Rare Fat Disorder

Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Year-End Results

Arrowhead Pharmaceuticals to Participate in Upcoming November 2025 Conferences

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Novartis

Arrowhead Pharmaceuticals Files CTA for Investigational ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

Arrowhead Pharmaceuticals Files Complaint for Declaratory Judgment Against Ionis Pharmaceuticals

Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies

Arrowhead Stock Rockets 11% Today – Retail Says $200M Upfront Payment From Novartis Collaboration Is ‘Hell Of A Deal’

Arrowhead Pharma Jumps After Inking A Deal Worth Up To $2.2 Billion

Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement

Arrowhead Pharmaceuticals to Participate in Upcoming September 2025 Conferences

Goodbye, Mag 7! These 3 Buy-Rated Small-Cap Stocks Are Starting to Outperform.

Arrowhead (ARWR) Climbs 24.9% on $100-Million Licensing Revenue

This Analyst Says Sarepta Lost Credibility By Exiting Arrowhead At A Loss, But Retail Sees Stock Hitting $30 By Next Week

Sarepta Sells Arrowhead Stake To Stretch Its Cash Runway; And One Stock Dives

Sarepta Keeps Retail Traders Bullish As Stock Surges On $100M Milestone Payment To Arrowhead In Genetic Disorder Trial

Arrowhead Pharmaceuticals Redeems Approximately $50 Million of Arrowhead Stock and Will Receive Approximately $50 Million in Cash in Satisfaction of Milestone from Sarepta Therapeutics

Arrowhead Pharmaceuticals Reports Fiscal 2025 Third Quarter Results